Literature DB >> 9195490

Effect of irradiation on transforming growth factor-beta secretion by malignant glioma cells.

E Satoh1, H Naganuma, A Sasaki, M Nagasaka, H Ogata, H Nukui.   

Abstract

Glioblastoma cells secrete transforming growth factor-beta (TGF-beta), which has a variety of immunosuppressive properties. We investigated the effect of irradiation TGF-beta secretion by malignant glioma cells. Three malignant glioma cell lines (T98G, A172, KG-1-C) were cultured and irradiated using 10 and 50 Gy Linac radiation. After further culture for 36 hours in serum-free culture medium, the supernatants were collected. The TGF-beta activity in the culture supernatants was determined using a specific bioassay. The levels of the active form and total TGF-beta in the supernatants from irradiated malignant glioma cells decreased compared to those from un-irradiated cells. However, since irradiation inhibited the growth of tumor cells, the amount of TGF-beta secretion per cell in irradiated cells tended to increase after irradiation. These results suggest that malignant glioma cells can still secrete TGF-beta and activate latent TGF-beta even after large dose irradiation, despite the inhibition of tumor growth.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9195490     DOI： 10.1023/a:1005791621265

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  34 in total

1.  Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2.

Authors:  M C Kuppner; M F Hamou; Y Sawamura; S Bodmer; N de Tribolet
Journal:  J Neurosurg       Date:  1989-08       Impact factor: 5.115

2.  Induction of anomalous killing activity from antigen-specific CTL clones by adding high doses of human recombinant interleukin 2.

Authors:  T Moriyama; G Suzuki; I Nakao; S Aizawa; K Okumura; T Nishimura; F Takaku
Journal:  Cell Immunol       Date:  1988-02       Impact factor: 4.868

3.  IL-1 alpha induces expression of active transforming growth factor-beta in nonproliferating T cells via a post-transcriptional mechanism.

Authors:  L A Bristol; F W Ruscetti; D T Brody; S K Durum
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

4.  Specific cytotoxic activity of T lymphocyte clones derived from a patient with gliosarcoma.

Authors:  S Miyatake; H Kikuchi; K Iwasaki; J Yamashita; Z Y Li; Y Namba; M Hanaoka
Journal:  J Neurosurg       Date:  1988-11       Impact factor: 5.115

5.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.

Authors:  M S Mahaley; W H Brooks; T L Roszman; D D Bigner; L Dudka; S Richardson
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

6.  Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.

Authors:  T Espevik; I S Figari; G E Ranges; M A Palladino
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

7.  Improved bioassay for the detection of transforming growth factor-beta 1 and beta 2 in malignant gliomas.

Authors:  H Naganuma; A Sasaki; E Satoh; T Sakihama; K Tasaka; H Nukui
Journal:  Neurol Med Chir (Tokyo)       Date:  1994-03       Impact factor: 1.742

8.  Early alterations in extracellular matrix and transforming growth factor beta gene expression in mouse lung indicative of late radiation fibrosis.

Authors:  J N Finkelstein; C J Johnston; R Baggs; P Rubin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-02-01       Impact factor: 7.038

9.  Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.

Authors:  J H Kehrl; A B Roberts; L M Wakefield; S Jakowlew; M B Sporn; A S Fauci
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

10.  Inhibition of tumor necrosis factor-alpha and -beta secretion by lymphokine activated killer cells by transforming growth factor-beta.

Authors:  H Naganuma; A Sasaki; E Satoh; M Nagasaka; S Nakano; S Isoe; K Tasaka; H Nukui
Journal:  Jpn J Cancer Res       Date:  1994-09
View more
  7 in total

1.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

2.  Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.

Authors:  Horatiu C Dancea; Mohammed M Shareef; Mansoor M Ahmed
Journal:  Mol Cell Pharmacol       Date:  2009

Review 3.  Cytokines: shifting the balance between glioma cells and tumor microenvironment after irradiation.

Authors:  Wei Zhou; Zheng Jiang; Xingang Li; Yangyang Xu; Zhenyu Shao
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-09       Impact factor: 4.553

Review 4.  Effects of radiation on metastasis and tumor cell migration.

Authors:  Marta Vilalta; Marjan Rafat; Edward E Graves
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

Review 5.  Allogeneic tumor cell vaccines: the promise and limitations in clinical trials.

Authors:  Sanjay Srivatsan; Jaina M Patel; Erica N Bozeman; Imade E Imasuen; Sara He; Danielle Daniels; Periasamy Selvaraj
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452

6.  Anti-Tumor Efficacy of an Adjuvant Built-In Nanovaccine Based on Ubiquitinated Proteins from Tumor Cells.

Authors:  Fang Huang; Jinjin Zhao; Yiting Wei; Zhifa Wen; Yue Zhang; Xuru Wang; Yanfei Shen; Li-Xin Wang; Ning Pan
Journal:  Int J Nanomedicine       Date:  2020-02-13

Review 7.  Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Authors:  Laure Malric; Sylvie Monferran; Julia Gilhodes; Sabrina Boyrie; Perrine Dahan; Nicolas Skuli; Julie Sesen; Thomas Filleron; Aline Kowalski-Chauvel; Elizabeth Cohen-Jonathan Moyal; Christine Toulas; Anthony Lemarié
Journal:  Oncotarget       Date:  2017-08-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.